Superior Purity and Protection for Sensitive Formulations
When it comes to protecting sensitive drug formulations, conventional glass containers may present challenges such as elevated leachable levels, pH variability, or potential delamination risks.
NEXGEN® PureGuard Vials are specifically developed to address these critical aspects through:
High-purity Type I borosilicate glass
Enhanced hydrolytic resistance
Tightly controlled manufacturing processes
The result is a highly uniform inner surface that supports formulation stability and significantly reduces the risk of glass–drug interaction.
Each vial undergoes comprehensive quality and analytical testing throughout production to ensure consistent performance and dependable protection of pharmaceutical products. This helps manufacturers:
Minimize formulation risks
Reduce development complexity
Maintain long-term drug stability
Suitable for a broad range of injectable therapies, NEXGEN® PureGuard Vials provide a reliable container solution built on quality, consistency, and regulatory confidence.
Switching to NEXGEN® PureGuard Vials is seamless for manufacturers already using Type I borosilicate glass formats, allowing process continuity while benefiting from enhanced container performance.
Manufactured from high-purity Type I Borosilicate Glass, NEXGEN® PureGuard Vials are designed to meet the stringent requirements of modern pharmaceutical development, including complex and high-value biologic therapies.
The optimized internal surface supports formulation stability across a wide range of products, helping to:
Reduce the risk of glass–drug interaction
Minimize the need for reformulation during development or scale-up
With controlled leachable profiles and stable pH performance, NEXGEN® PureGuard Vials provide reliable protection for:
Water for Injection (WFI)
Sodium Chloride solutions
Buffer solutions, including phosphate buffers
Diluents and reconstitution solutions
These characteristics make NEXGEN® PureGuard Vials a dependable container choice for maintaining drug integrity, reducing the risk of delamination, and supporting long-term product stability throughout the lifecycle of injectable therapies.
Headquarters 124-128 City Road
EC1V2NX London
Industrial address Highwork Road Swindon
SN34TZ United Kingdom
Share capital 1,300.000.00
© 2026 NexGen Pharma Pack. All rights reserved. Website by Zenbyte.